JP2009536834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536834A5 JP2009536834A5 JP2009511179A JP2009511179A JP2009536834A5 JP 2009536834 A5 JP2009536834 A5 JP 2009536834A5 JP 2009511179 A JP2009511179 A JP 2009511179A JP 2009511179 A JP2009511179 A JP 2009511179A JP 2009536834 A5 JP2009536834 A5 JP 2009536834A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr2
- antibody
- agent
- gene
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 13
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 101150088071 fgfr2 gene Proteins 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 230000003321 amplification Effects 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000013068 control sample Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000004544 DNA amplification Effects 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79977206P | 2006-05-12 | 2006-05-12 | |
| PCT/US2007/068737 WO2007134210A2 (en) | 2006-05-12 | 2007-05-11 | Methods and compositions for the diagnosis and treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536834A JP2009536834A (ja) | 2009-10-22 |
| JP2009536834A5 true JP2009536834A5 (enExample) | 2010-07-01 |
Family
ID=38694721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511179A Pending JP2009536834A (ja) | 2006-05-12 | 2007-05-11 | 癌の診断及び治療のための方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8945572B2 (enExample) |
| EP (1) | EP2018442A2 (enExample) |
| JP (1) | JP2009536834A (enExample) |
| CA (1) | CA2651755A1 (enExample) |
| WO (1) | WO2007134210A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| JP2009536834A (ja) * | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| DK2842573T3 (en) | 2008-11-07 | 2017-10-30 | Galaxy Biotech Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
| US20100136560A1 (en) * | 2008-12-02 | 2010-06-03 | The Johns Hopkins University | Integrated Analyses of Breast and Colorectal Cancers |
| WO2011025814A1 (en) * | 2009-08-25 | 2011-03-03 | National Jewish Health | Methods and compositions for treatment of lung injury |
| EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
| US8614183B2 (en) | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| SG185487A1 (en) * | 2010-05-11 | 2012-12-28 | Aveo Pharmaceuticals Inc | Anti-fgfr2 antibodies |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| EP2723924A4 (en) * | 2011-06-22 | 2015-03-25 | Oncocyte Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| SG11201403085PA (en) | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| JPWO2014007369A1 (ja) * | 2012-07-05 | 2016-06-02 | 国立研究開発法人国立がん研究センター | Ｆｇｆｒ２融合遺伝子 |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| PE20160190A1 (es) | 2013-08-01 | 2016-04-28 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
| BR112018010410A8 (pt) * | 2015-11-23 | 2019-02-26 | Five Prime Therapeutics Inc | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 |
| CN110621336B (zh) | 2017-05-16 | 2024-05-14 | 戊瑞治疗有限公司 | 癌症治疗中抗fgfr2抗体与化学治疗剂的组合 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| US6900053B2 (en) | 2001-09-14 | 2005-05-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 2 expression |
| AU756731C (en) | 1998-02-25 | 2004-07-29 | Canton Of Basel-Stadt | Cellular arrays for rapid molecular profiling |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| EP1131470A4 (en) * | 1998-10-28 | 2004-11-10 | Vysis Inc | CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS |
| JP2002533726A (ja) | 1998-12-28 | 2002-10-08 | サネシス ファーマシューティカルス インコーポレイテッド | 結合のための小有機分子リガンドの同定 |
| IL128380A0 (en) * | 1999-02-04 | 2000-01-31 | Yeda Res & Dev | A method of screening for agonists and antagonists of FGFR |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| WO2001094583A2 (en) | 2000-06-07 | 2001-12-13 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7537905B2 (en) | 2003-01-15 | 2009-05-26 | The Regents Of The University Of California | Amplified and overexpressed gene in colorectal cancers |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| WO2005115363A2 (en) * | 2004-05-25 | 2005-12-08 | Yale University | Method for treating skeletal disorders resulting from fgfr malfunction |
| JP2008535853A (ja) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌関連遺伝子 |
| JP2009536834A (ja) * | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
-
2007
- 2007-05-11 JP JP2009511179A patent/JP2009536834A/ja active Pending
- 2007-05-11 US US12/300,156 patent/US8945572B2/en not_active Expired - Fee Related
- 2007-05-11 EP EP07783628A patent/EP2018442A2/en not_active Ceased
- 2007-05-11 CA CA002651755A patent/CA2651755A1/en not_active Abandoned
- 2007-05-11 WO PCT/US2007/068737 patent/WO2007134210A2/en not_active Ceased
-
2014
- 2014-12-17 US US14/574,292 patent/US20150167101A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536834A5 (enExample) | ||
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Sharma et al. | Tuberculosis: an overview of the immunogenic response, disease progression, and medicinal chemistry efforts in the last decade toward the development of potential drugs for extensively drug-resistant tuberculosis strains | |
| Rosenberg et al. | A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma | |
| Markham | Idelalisib: first global approval | |
| Zhou et al. | Collapse of DNA tetrahedron nanostructure for “off–on” fluorescence detection of DNA methyltransferase activity | |
| Bauss et al. | Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy | |
| Han et al. | Single-antibody, targeted nanoparticle delivery of camptothecin | |
| JP2016503295A5 (enExample) | ||
| Shigdar et al. | Profiling cancer cells by cell-SELEX: use of aptamers for discovery of actionable biomarkers and therapeutic applications thereof | |
| Maity et al. | Targeting the epidermal growth factor receptor with molecular degraders: state-of-the-art and future opportunities | |
| WO2010063011A3 (en) | Methods for the treatment of infections and tumors | |
| JP2007516232A5 (enExample) | ||
| JP2015536950A (ja) | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 | |
| JP2013531655A5 (enExample) | ||
| Sharif-Zak et al. | CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender | |
| Kulkarni et al. | Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2 | |
| KR20160137599A (ko) | C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계 | |
| JP2017502014A5 (enExample) | ||
| Salama et al. | Targeted protein degradation: clinical advances in the field of oncology | |
| Wallace-Povirk et al. | Folate transport and one-carbon metabolism in targeted therapies of epithelial ovarian cancer | |
| Bose et al. | Tuberculosis: current scenario, drug targets, and future prospects | |
| Sujith et al. | Aptamers: precision tools for diagnosing and treating infectious diseases | |
| Lau et al. | Aptamer-based bio-barcode assay for the detection of cytochrome-c released from apoptotic cells | |
| Tan et al. | Aptamer enables consistent maytansine delivery through maintaining receptor homeostasis for HER2 targeted cancer therapy |